ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 12, 2023 -- For patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) yields five-year progression-free survival (PFS) of 28.5 percent and overall survival of 40.3 percent, according to a study presented at the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in San Diego.
Jay Y. Spiegel, M.D., from the Miller School of Medicine at the University of Miami, and colleagues reported outcomes of patients receiving axi-cel, including 42 percent who did not meet the eligibility criteria for the ZUMA-1 trial; 298 patients underwent leukapheresis as part of the CAR T-cell process.
The researchers found that median overall survival was 34.9 months after a median follow-up of 58 months, with overall survival of 49.1, 43.0, and 40.3 percent at three, four, and five years, respectively. Median progression-free survival was 8.7 months, with PFS of 36.1, 30.7, and 28.5 percent at three, four, and five years, respectively. Reduced overall survival was seen in association with male sex, lactate dehydrogenase above the upper limit of normal, ECOG status of 2 to 4, and elevated bilirubin >1.5 (hazard ratios, 1.56, 1.6, 2.02, 5.68, respectively). During the follow-up period, 191 PFS events occurred after axi-cel infusion, including 151 due to lymphoma progression and 40 nonrelapse mortality events. Of the 40 nonrelapse mortality events, 21 were secondary to infection and nine were attributed to secondary malignancy.
"We were very encouraged by the results," Spiegel said in a statement. "Often, results from clinical trials don't translate to the larger population. But we were sobered by the rates of nonrelapse mortality and that is where we need to improve."
Several authors disclosed financial ties to biopharmaceutical companies, including Kite Gilead, the manufacturer of axi-cel.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
THURSDAY, April 25, 2024 -- For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) T-cell therapy followed by...
Second Primary Malignancy Risk Increased After Cutaneous B-Cell Lymphoma
WEDNESDAY, April 3, 2024 -- Patients with primary cutaneous B-cell lymphomas (PCBCLs) have an increased risk for second primary malignancies (SPMs), according to a study published...
Survival 21 Percent a Year After ICU Discharge for Blood Cancer Patients
THURSDAY, March 21, 2024 -- For hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.